Hepatic veno-occlusive disease after tranexamic acid administration in oatients undergoing allogeneic hematopoietic stem cell transplantation

Takehiko Mori, Yoshinobu Aisa, Takayuki Shimizu, Rie Yamazaki, Ai Mihara, Tomoharu Yajima, Toshifumi Hibi, Yasuo Ikeda, Shinichiro Okamoto

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Tranexamic acid is one of the widely used antifibrinolytic agents. In spite of its effective inhibitory activity against plasminogen, thromboembolic adverse events caused by tranexamic acid are rare. We encountered three recipients of allogeneic hematopoietic stem cell transplantation (HSCT) who developed hepatic veno-occlusive disease (VOD) shortly after the administration of tranexamic acid. Hepatic VOD was resolved completely in all patients with the discontinuation of the drug, and with supportive measures with or without intravenous tissue plasminogen activator administration. These findings suggest that administration of tranexamic acid could be one of the possible risk factors for developing hepatic VOD in HSCT recipients.

Original languageEnglish
Pages (from-to)838-839
Number of pages2
JournalAmerican Journal of Hematology
Volume82
Issue number9
DOIs
Publication statusPublished - 2007 Sep

Fingerprint

Hepatic Veno-Occlusive Disease
Tranexamic Acid
Hematopoietic Stem Cell Transplantation
Antifibrinolytic Agents
Plasminogen
Tissue Plasminogen Activator
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Hematology

Cite this

Hepatic veno-occlusive disease after tranexamic acid administration in oatients undergoing allogeneic hematopoietic stem cell transplantation. / Mori, Takehiko; Aisa, Yoshinobu; Shimizu, Takayuki; Yamazaki, Rie; Mihara, Ai; Yajima, Tomoharu; Hibi, Toshifumi; Ikeda, Yasuo; Okamoto, Shinichiro.

In: American Journal of Hematology, Vol. 82, No. 9, 09.2007, p. 838-839.

Research output: Contribution to journalArticle

@article{479e12cafbc64bfdabf580f01ba4b048,
title = "Hepatic veno-occlusive disease after tranexamic acid administration in oatients undergoing allogeneic hematopoietic stem cell transplantation",
abstract = "Tranexamic acid is one of the widely used antifibrinolytic agents. In spite of its effective inhibitory activity against plasminogen, thromboembolic adverse events caused by tranexamic acid are rare. We encountered three recipients of allogeneic hematopoietic stem cell transplantation (HSCT) who developed hepatic veno-occlusive disease (VOD) shortly after the administration of tranexamic acid. Hepatic VOD was resolved completely in all patients with the discontinuation of the drug, and with supportive measures with or without intravenous tissue plasminogen activator administration. These findings suggest that administration of tranexamic acid could be one of the possible risk factors for developing hepatic VOD in HSCT recipients.",
author = "Takehiko Mori and Yoshinobu Aisa and Takayuki Shimizu and Rie Yamazaki and Ai Mihara and Tomoharu Yajima and Toshifumi Hibi and Yasuo Ikeda and Shinichiro Okamoto",
year = "2007",
month = "9",
doi = "10.1002/ajh.20958",
language = "English",
volume = "82",
pages = "838--839",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "9",

}

TY - JOUR

T1 - Hepatic veno-occlusive disease after tranexamic acid administration in oatients undergoing allogeneic hematopoietic stem cell transplantation

AU - Mori, Takehiko

AU - Aisa, Yoshinobu

AU - Shimizu, Takayuki

AU - Yamazaki, Rie

AU - Mihara, Ai

AU - Yajima, Tomoharu

AU - Hibi, Toshifumi

AU - Ikeda, Yasuo

AU - Okamoto, Shinichiro

PY - 2007/9

Y1 - 2007/9

N2 - Tranexamic acid is one of the widely used antifibrinolytic agents. In spite of its effective inhibitory activity against plasminogen, thromboembolic adverse events caused by tranexamic acid are rare. We encountered three recipients of allogeneic hematopoietic stem cell transplantation (HSCT) who developed hepatic veno-occlusive disease (VOD) shortly after the administration of tranexamic acid. Hepatic VOD was resolved completely in all patients with the discontinuation of the drug, and with supportive measures with or without intravenous tissue plasminogen activator administration. These findings suggest that administration of tranexamic acid could be one of the possible risk factors for developing hepatic VOD in HSCT recipients.

AB - Tranexamic acid is one of the widely used antifibrinolytic agents. In spite of its effective inhibitory activity against plasminogen, thromboembolic adverse events caused by tranexamic acid are rare. We encountered three recipients of allogeneic hematopoietic stem cell transplantation (HSCT) who developed hepatic veno-occlusive disease (VOD) shortly after the administration of tranexamic acid. Hepatic VOD was resolved completely in all patients with the discontinuation of the drug, and with supportive measures with or without intravenous tissue plasminogen activator administration. These findings suggest that administration of tranexamic acid could be one of the possible risk factors for developing hepatic VOD in HSCT recipients.

UR - http://www.scopus.com/inward/record.url?scp=35748958758&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35748958758&partnerID=8YFLogxK

U2 - 10.1002/ajh.20958

DO - 10.1002/ajh.20958

M3 - Article

C2 - 17506069

AN - SCOPUS:35748958758

VL - 82

SP - 838

EP - 839

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 9

ER -